Health Care [ 12/12 ] | Life Sciences Tools & Services [ 71/74 ]
NASDAQ | Common Stock
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products.
The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services.
It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function.
In addition, it offers phytochemical reference standards, and other research and development services.
The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States.
ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 24 | -0.00 Increased by +99.33% | -0.02 Increased by +99.00% |
| May 8, 24 | -0.01 Increased by +66.67% | -0.02 Increased by +50.00% |
| Mar 6, 24 | 0.00 Increased by +107.50% | -0.03 Increased by +105.00% |
| Nov 8, 23 | -0.01 Increased by +75.00% | -0.03 Increased by +66.67% |
| Aug 9, 23 | -0.03 Increased by +66.67% | -0.04 Increased by +25.00% |
| May 10, 23 | -0.03 Increased by +72.73% | -0.05 Increased by +40.00% |
| Mar 8, 23 | -0.02 Increased by +75.00% | -0.02 |
| Nov 2, 22 | -0.04 Increased by +69.23% | -0.06 Increased by +33.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 34.92 M Increased by +79.12% | 1.88 M Increased by +295.83% | Increased by +5.38% Increased by +209.33% |
| Jun 30, 24 | 22.74 M Increased by +11.89% | -15.00 K Increased by +99.32% | Decreased by -0.07% Increased by +99.39% |
| Mar 31, 24 | 22.15 M Decreased by -1.79% | -492.00 K Increased by +63.01% | Decreased by -2.22% Increased by +62.33% |
| Dec 31, 23 | 21.20 M Increased by +0.95% | 114.00 K Decreased by -83.06% | Increased by +0.54% Decreased by -83.22% |
| Sep 30, 23 | 19.50 M Increased by +14.25% | -959.00 K Decreased by -187.58% | Decreased by -4.92% Decreased by -176.65% |
| Jun 30, 23 | 20.32 M Increased by +21.46% | -2.19 M Increased by +65.80% | Decreased by -10.78% Increased by +71.85% |
| Mar 31, 23 | 22.56 M Increased by +30.69% | -1.33 M Increased by +82.83% | Decreased by -5.90% Increased by +86.87% |
| Dec 31, 22 | 21.00 M Increased by +18.23% | 673.00 K Increased by +112.64% | Increased by +3.21% Increased by +110.69% |